Alivus Life Sciences Limited has informed the Exchange about Investor Presentation
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alivus Life Sciences reported FY26 revenue of ₹25,518 Mn (up 6.9% YoY) with EBITDA of ₹8,577 Mn (up 19.6% YoY) and PAT of ₹5,645 Mn (up 16.2% YoY). EBITDA margins expanded significantly by 360 bps to 33.6%, while PAT margins improved by 180 bps to 22.1%. The company generated strong free cash flow of ₹2,590 Mn, ending with cash and equivalents of ₹7,824 Mn. Non-GPL business grew 13% and now contributes 71% of total revenue, while the CDMO business delivered an 18% YoY turnaround. For FY27, management remains confident of delivering high single-digit revenue growth with margins sustained above 30%.
Strong margin expansion and cash generation signal operational efficiency improvements; the FY27 guidance of sustained margins above 30% is positive for shareholders and suggests the stock could rerate higher if growth targets are met.